Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin Alfa Dosing Strategies in CKD on Hemodialysis
NCT02253654Phase 4Completed
- Sponsor
- Amgen
- Start
- Apr 2015
- Primary completion
- Apr 2016
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 2
01
Overview
A Phase 4 trial of epoetin alfa in anemia, sponsored by Amgen. Started Apr 2015; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT02253654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253654.